Novel Mono-Substituted 4H-1,2,6-Thiadiazines with Antioxidant and Anti-Lipoxygenase Activities Authors: Eleftherios Charissopoulos, Panayiotis A Koutentis, Andreas S Kalogirou, Eleni Pontiki, Abby Parrill Published: 2025 ABSTRACT AbstractΤhe synthesis of a novel series of mono-substituted 4H-1,2,6-thiadiazine derivatives was reported, aiming at enhancing antioxidant and lipoxygenase inhibitory activities via pharmacophore combination. The compounds were prepared from 3,5-dichloro-4H-1,2,6-thiadiazin-4-one and 2-(3,5-dichloro-4H-1,2,6-thiadiazin-4-ylidene)malononitrile. All the derivatives were evaluated for radical scavenging activity towards 2,2-diphenyl-1-picrylhydrazyl (DPPH), 2,2′-azobis(2-methylpropionamidine) dihydrochloride (AAPH)-induced lipid peroxidation inhibition, and soybean lipoxygenase (sLOX) inhibition. The compounds exhibited moderate to good antioxidant activity and variable sLOX inhibition. Notably, 2-[3-(benzo[d]oxazol-2-ylthio)-5-chloro-4H-1,2,6-thiadiazin-4-ylidene]malononitrile showed the strongest antioxidant effect (92% DPPH scavenging at 60 min and 70% inhibition of AAPH-induced lipid peroxidation) but low sLOX inhibition, whereas 3-chloro-5-(4-phenylpiperazin-1-yl)-4H-1,2,6-thiadiazin-4-one displayed the most potent sLOX inhibition (IC50: 7.5 μM), with a docking score of −8.3 kcal/mol developing hydrophobic interactions with Phe134 and Val520.Keywords: heterocycle; 1,2,6-thiadiazine; antioxidants; lipoxygenase; anti-inflammatory 1. Introduction 1.1. Interplay Between Inflammation and Oxidative Stress Oxidative stress (OS) and inflammation are interconnected processes that not only serve protective roles but are also essential in maintaining physiological homeostasis [1]. Inflammation is a fundamental response of the immune system, typically triggered by invading pathogens or physical injury (Figure 1) [2,3,4]. The main microcirculatory events of the inflammatory phase include increased vascular permeability, leukocyte recruitment and accumulation, and the release of inflammatory mediators [5]. Oxidative stress occurs when the balance between oxidants and antioxidants is disrupted (Figure 1), resulting in tissue damage [6]. During OS, inflammatory mediators are generated, which in turn enhance the production of reactive oxygen species (ROS) [7,8]. Targeting the excessive generation of reactive oxygen species (ROS) has emerged as a clinically significant strategy for managing diseases driven by chronic inflammation [9]. (A) Schematic representation of mitochondrial involvement in oxidative stress. Molecular oxygen (O2) undergoes partial reduction, generating superoxide anion (O2.−). O2.− is then converted into hydrogen peroxide (H2O2) by superoxide dismutase (SOD), which is subsequently reduced to water (H2O) by glutathione peroxidase (GPX). This pathway shows how mitochondria balance ROS production with antioxidant defenses. (B) Schematic overview of the inflammatory response. The figure illustrates the recruitment and activation of mast cells, macrophages, neutrophils, and lymphocytes, and the presence of red blood cells within the vasculature. 1.2. 1,2,6-Thiadiazines: Structure and Biological Functions 1,2,6-Thiadiazines are sulfur–nitrogen heterocycles with diverse applications [10]. Non-S-oxidized 4H-1,2,6-thiadiazines are rare, but find uses in the biological [11,12,13,14,15,16] as well as the materials sciences [17,18,19,20,21,22]. Their chemistry and applications have recently been reviewed [23]. Current research on thiadiazines primarily centers on three key starting materials, 3,4,4,5-tetrachloro-4H-1,2,6-thiadiazine (1), ketone 2 (see Figure S1 in the Supporting Information for its synthesis, SI), and ylidenemalononitrile 3 (Scheme 1). Formation of thiadiazines 2 and 3. This research work is focused on mono-substituted 1,2,6-thiadiazines as antioxidants. A small library of monosubstituted 3-amino and 3-thiothiadiazines (Table 1 and Table 2) was investigated. Interestingly, 1,2,6-thiadiazines 4 can be oxidized by a range of oxidants (N2O4, m-CPBA, Oxone, PIFA, and PIDA) to give oxidation of the endocyclic sulfur to either sulfoxides 5 or sulfones 6 [24] (Scheme 2). Moreover, the photochemical treatment of 4H-1,2,6-thiadiazines 7 with visible light and air (or 3O2) afforded ring-contracted 1,2,5-thiadiazole 1-oxides 8 in good yields under both batch and flow conditions [23,25] (Scheme 2, see Figure S2, SI for the reaction mechanism). Oxidations of selected 4H-1,2,6-thiadiazinones 4 and 7 [22,23]. Additionally, other thiadiazine isomers have previously been explored for a broad spectrum of biological activities. For example, a series of 1,3,4-thiadiazine–coumarin hybrids has been investigated for their antioxidative and antifungal properties. Other thiadiazine derivatives have been reported as potential antiparasitic, antioxidant, anticancer, antibacterial, and antifungal agents (Scheme 3) [26,27,28]. Compounds I–IV were evaluated for DPPH scavenging activity and antifungal effects against A. flavus, showing promising results [27]. Compound V exhibited notable antibacterial and antifungal properties [26], while compounds VI [26] and VII [28] emerged as promising candidates for future anticancer and antiparasitic studies, respectively. Recent studies have also highlighted that thiadiazines, due to their resemblance to cephalosporins, can play a pivotal role in bacterial resistance by inhibiting the NorA pump [28]. Structures of thiadiazine derivatives exhibiting potential antiparasitic, antioxidant, anticancer, antibacterial, and antifungal activities (I–VII) [26,27,28]. In light of these findings, a series of 1,2,6-thiadiazines was assessed for their capacity to (i) neutralize the stable DPPH free radical; (ii) inhibit linoleic acid peroxidation, and (iii) inhibit soybean lipoxygenase as a marker of anti-inflammatory activity. 2. Results and Discussion 2.1. Synthesis Ιnitially the selective mono-displacement of dichlorothiadiazines 2 and 3 with selected amine nucleophiles was investigated. N-Substituted piperazines, such as 1-phenylpiperazine and 1-benzhydrylpiperazine, were selected. Piperazines are privileged scaffolds [29,30] in drug discovery, as they often improve the solubility and pharmacokinetic properties of bioactive molecules. The reactions proceeded smoothly, affording four new 3-aminothiadiazines 9a,b and 10a,b in high yields (Table 1). Table 1Synthesis of 3-aminothiadiazine targets.CompoundARConditions(Time, h)Yield(%)9aOPhA (1)979bOCHPh2A (1)9910aC(CN)2PhB (1)8810bC(CN)2CHPh2B (1)100 Synthesis of 3-aminothiadiazine targets. Subsequently, the mono-displacement of dichlorothiadiazines 2 and 3 with a number of aromatic and heteroaromatic thiols to prepare 3-thiothiadiazines was explored. Interestingly, dichlorothiazinone 2 gave good yields of sulfides 11 (43–81%) with the exception of tetrazole thiols (28 and 39%, Table 2, 11b & 11e) and 6-ethoxybenzothiazol thiol (43%, Table 2, 11i) that gave low yields. The three examples of thiol displacement of dicyanoylidene 3 all gave medium yields of sulfides 12 (49–71%, Table 2, 12a–c). Compound 11h has been previously reported in the literature [31]. For all the compounds, the identification was carried out by melting point, IR, MS, and 1H and 13C NMR (see SI for NMR spectra). Table 2Synthesis of 3-thiothiadiazine targets.CompoundARTime (h)Yield (%)11aO4-Me-pyrimid-2-yl248111bO1-Methyl-1H-tetrazol-5-yl52811cOBenzo[d]oxazol-2-yl207411dO4-Phenylacetamide18111eO1-Ph-1H-tetrazol-5-yl53911fO4-Me-4H-1,2,4-triazol-3-yl38111gOThiazol-2-yl17311hOBenzo[d]thiazol-2-yl2471 a11iO6-EtO-benzo[d]thiazol-2-yl24312aC(CN)24-Me-pyrimid-2-yl0.57112bC(CN)21-Me-1H-tetrazol-5-yl3.55612cC(CN)2Benzo[d]oxazol-2-yl349a Prepared according to the literature [31]. Synthesis of 3-thiothiadiazine targets. a Prepared according to the literature [31]. 2.2. Physicochemical Studies 2.2.1. Determination of Lipophilicity Lipophilicity is an important property of a drug candidate, as it affects solubility and how easily the molecule crosses cell membranes, which in turn influences its ADMET profile (absorption, distribution, metabolism, elimination, and toxicity) [32,33]. Lipophilicity (expressed as clogP values) was theoretically calculated using the Bio-Loom program from BioByte Corp (http://www.biobyte.com/, accessed on 10 June 2025). 2.2.2. Theoretical Calculation of Physicochemical Properties Drug-likeness refers to the likelihood that a molecule can become an orally bioavailable drug. In practice, it is evaluated by comparing the physicochemical and structural properties of a new compound to those of established drugs. ADMET profiles can often be estimated directly from a molecule’s structure, ideally even before its synthesis and biological testing. To support this, numerous in silico tools have been established for predicting ADMET characteristics. Among these is the online platform Molinspiration (www.molinspiration.com, Molinspiration Cheminformatics 2025, 9 September 2025). On this platform, drug-likeness is evaluated using Lipinski’s Rule of Five. The parameters calculated include miLogP (lipophilicity); TPSA (topological polar surface area), an important indicator of drug absorption and bioavailability; Natoms (total atom count); MW (molecular weight), which influences absorption, distribution, and overall drug-likeness; nON (hydrogen bond acceptors); nOHNH (hydrogen bond donors), which affect hydrogen-bonding potential and target affinity; Nviolations (number of Lipinski’s rule of five violations); Nrotb (rotatable bonds), reflecting molecular flexibility and oral bioavailability; and Volume (three-dimensional molecular size), impacting membrane permeability and steric compatibility. All the synthesized compounds do not present any violations. The results are presented in Table 3. Table 3Drug-likeness studies of synthesized compounds.CompdMilog P aTPSA bNo of AtomsNo of O and N cNo of OH and NH dNo of ViolationsNo of Rotational Bonds eVolume fMW gClog P h 9a 2.749.33205002252.30308.792.12 9b 4.1849.33275004340.54398.924.21 10a 3.0579.84246002294.46356.841.69 10b 4.5379.84316004382.69446.973.75 11a 1.9268.64165002196.75272.741.32 11b 1.0186.47157002177.96262.710.66 11c 3.2268.89185002209.90297.752.54 11d 2.3671.95195103236.45313.791.87 11e 2.2886.47207003232.81324.781.81 11f 1.1573.57156002182.11261.720.34 11g 2.3655.75144002175.05263.761.61 11h 3.8655.75184002219.05313.823.21 11i 4.2764.98215004261.39357.874.03 12a 2.2799.15206002238.90320.790.63 12b 1.35116.98198002220.11310.750.88 12c 3.5799.4226002252.05345.800.6a Logarithm of partition coefficient between n-octanol and water (milog P); b Topological polar surface area (TPSA); c number of hydrogen bond acceptors; d number of hydrogen bond donors; e number of rotatable bonds; f molecular volume; g molecular weight; h theoretically calculated lipophilicity. Drug-likeness studies of synthesized compounds. a Logarithm of partition coefficient between n-octanol and water (milog P); b Topological polar surface area (TPSA); c number of hydrogen bond acceptors; d number of hydrogen bond donors; e number of rotatable bonds; f molecular volume; g molecular weight; h theoretically calculated lipophilicity. 2.3. Biological Evaluation The synthesized compounds were evaluated in vitro for their ability to interact with the stable free radical DPPH, inhibit the AAPH-induced linoleic acid peroxidation, and suppress soybean lipoxygenase activity. The synthesized derivatives were tested for their interaction with the stable free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH) at a concentration of 100 μM after 20 and 60 min (Table 4). DPPH is widely used as a standard method for evaluating antioxidant activity [34]. Interestingly, the interaction between lipophilic compounds and DPPH is not dictated by lipophilicity alone. The antioxidant’s molecular structure, the solvent environment, and several experimental conditions can significantly influence this behavior. However, lipophilic compounds typically dissolve efficiently in organic solvents when they react with DPPH. The relationship between antioxidant activity and lipophilicity was reported in previous studies [35]. Nordihydroguaiaretic acid (NDGA) was used as a reference standard [36]. Table 4Interaction with DPPH at 20 and 60 min, inhibition of AAPH-induced linoleic acid peroxidation (AAPH%), and in vitro inhibitory activity against soybean lipoxygenase (expressed as % inhibition and IC50) were evaluated for the synthesized compounds.CompoundRA%, DPPH, 20 min(100 µM)RA%, DPPH, 60 min(100 µM)LOX% Inhibition 100 μMor IC50 (μM)%AAPH(100 µM) 9a 767.5 μM15 9b 2255 μM20 10a 161546%27 10b nono67.5 μMNo 11a 2no31%No 11b 3344%45 11c 212277.5 μM5 11d 1285 μM43 11e 151750%No 11f 101252.5 μM7 11g 10740%No 11h 8133%No 11i 3no67.5 μMNo 12a 829041%18 12b 273675 μMNo 12c 899227%70 ΝDGA 879393%0.45 μM (93%)- Trolox ---93no: no action under the experimental conditions. Standard deviation (±SD) of the mean is less than <10%. For the in vitro assays, the mean value is derived from at least six independent experiments. Interaction with DPPH at 20 and 60 min, inhibition of AAPH-induced linoleic acid peroxidation (AAPH%), and in vitro inhibitory activity against soybean lipoxygenase (expressed as % inhibition and IC50) were evaluated for the synthesized compounds. no: no action under the experimental conditions. Standard deviation (±SD) of the mean is less than <10%. For the in vitro assays, the mean value is derived from at least six independent experiments. Among the 9a,b, 10a,b, and 11a–i series, none of the compounds exhibited significant DPPH radical scavenging activity at 20 or 60 min. Moreover, the interaction with DPPH was not time-dependent. Among these series, compound 11c showed the highest activity, with 21% at 20min, which seems to be stable over time (22% interaction at 60 min). From the 11 series, compound 11c, which contains the benzo[d]oxazol-2-yl substitution, presented the highest interaction with DPPH, but still moderate compared to the reference compound. Compounds 12a–c exhibited the most potent activity, with compounds 12a and 12c showing excellent interactions of 90% and 92%, respectively, at 60 min, compared to NDGA (87%). The interaction of compounds 12a–c with the DPPH radical appears to increase over time. Compound 12c, which contains a benzo[d]oxazol-2-yl moiety, again emerged as the most active compound, similar to the 11-series. The results indicate that the presence of a 4-dicyanoylidine group on the thiadiazine instead of a ketone enhances DPPH interaction, as evidenced by the greater increase in % interaction values observed for compounds 12a–c compared to the corresponding compounds 11a–c. In the lipid peroxidation assay, sodium linoleate was used as the substrate, while 2,2′-azobis(2-methylpropionamidine) dihydrochloride (AAPH) was the peroxyl radical initiator. The formation of 13-hydroperoxy-linoleic acid from linoleic acid was observed by UV-Vis absorption measurements at 234 nm. Trolox was used as a reference compound. Most of the synthesized compounds exhibited moderate to low inhibitory activity, except for compound 12c, with 70% anti-lipid peroxidation. Among the 9a,b and 10a,b series, all of them showed low inhibitory activity, with compound 10a having the best one with 27%. Among the 11a–i series, the compounds exhibited moderate to low activity, with 11b and 11d showing the highest values of 45% and 43%, respectively. Among the 12a–c series, compound 12c, which contains the benzo[d]oxazol-2-yl moiety, showed excellent AAPH inhibitory effect (70%). Comparison between the 11a–c and 12a–c series revealed that the presence of a 4-dicyanoylidine group in the thiadiazine instead of a ketone favors AAPH inhibition, with the exception of the comparison between compounds 11b and 12b. Lipoxygenase (LOX) plays a key role in the formation of leukotrienes, which are important inflammatory mediators [37]. Leukotrienes are considered key therapeutic targets in inflammatory diseases due to their role. Soybean lipoxygenase (LOX), a plant-based enzyme, has long been used as a model system to study the structural and functional characteristics of the lipoxygenase family [38] due to its significant homology with human 5-LOX [39]. NDGA was used as a reference drug. Based on the IC50 values, the compounds generally exhibited moderate to low inhibitory effects, with the exception of compound 9a, which presented an IC50 value of 7.5 µM and A: O and R: Ph substitution. Comparison of the pairs 9a,b and 10a,b suggests that in this case, the presence of a 4-ketone group in the thiadiazine instead of a dicyanoylidine is more favorable for sLOX inhibition. Among the 11a–i series, compounds 11f, 11i, 11c, and 11d exhibited moderate inhibitory effects, with IC50 values of 52.5, 67.5, 77.5, and 85 µM, respectively. Compound 11f, bearing a 4-Me-4H-1,2,4-triazol-3-yl substitution, presented slightly better results within the 11-series with an IC50 of 52.5 µM. Comparison of the 11a–c and 12a–c series suggests that within these series, the presence of a 4-dicyanoylidine group in the thiadiazine instead of a ketone enhances the anti-LOX inhibition, with the exception of compounds 11c and 12c. 2.4. Docking Simulation Soybean Lipoxygenase Studies Soybean lipoxygenase-1(PDB ID: 3PZW) was selected for the docking studies. The crystal structure of soybean lipoxygenase-1 (PDB ID: 3PZW) lacks a co-crystallized ligand. Thus, potential allosteric binding pockets outside the established iron-binding and substrate-binding sites have been identified, as highlighted in recent studies. Detsi, A. et al. [40] have detected three potential binding sites using SiteMap’s [41]. Researchers have identified Site 1 between the amino-terminal β-barrel (PLAT domain) and the α-helical domain that contains the catalytic iron. This is recognized as a potential binding site in blind docking studies [40]. Sites 2 and 3 are positioned within the α-helical segment as well. Consistent with previous studies, blind docking was performed to explore all potential binding sites. The results indicate that the compounds preferentially bind to Site 1, which aligns with the findings discussed earlier. Compound 9a was the most potent, presenting a binding score of −8.3 kcal/mol. Compound 9a develops hydrophobic interactions with the amino acids Phe134 and Val520 (Figure 2). The 3D preferred docking pose of compound 9a (depicted in cyan) bound to soybean lipoxygenase. Iron appears as an orange sphere. 3. Materials and Methods 3.1. Materials and Instruments The reaction mixture was monitored by TLC using commercial glass-backed thin-layer chromatography (TLC) plates (Merck Kieselgel 60 F254, Merck, Darmstadt, Germany). The plates were observed under UV light at 254 and 365 nm. Tetrahydrofuran (THF) was distilled over CaH2 before use. Melting points were determined using a PolyTherm-A, Wagner & Munz, Kofler Hotstage Microscope apparatus (Wagner & Munz, Munich, Germany). The solvent used for recrystallization is indicated after the melting point. The UV-vis spectrum was obtained using a Perkin-Elmer Lambda-25 UV/vis spectrophotometer (Perkin-Elmer, Waltham, MA, USA), and inflections are identified by the abbreviation “inf”. The IR spectrum was recorded on a Shimadzu FTIR-NIR Prestige-21 spectrometer (Shimadzu, Kyoto, Japan) with Pike Miracle Ge ATR accessory (Pike Miracle, Madison, WI, USA), and strong, medium, and weak peaks are represented by s, m, and w, respectively. 1H and 13C NMR spectra were recorded on a Bruker Avance 300 (at 300 and 75 MHz, respectively), or a 500 machine (at 500 and 125 MHz, respectively) (Bruker, Billerica, MA, USA). Deuterated solvents were used for homonuclear lock, and the signals are referenced to the deuterated solvent peaks. Attached proton test (APT) NMR studies were used for the assignment of the 13C peaks as CH3, CH2, CH, and Cq (quaternary). The Matrix-Assisted Laser Desorption/Ionization-Time of Flight (MALDI-TOF) mass spectrum (+ve mode) was recorded on a Bruker Autoflex III Smartbeam instrument (Bruker), while ESI-APCI+ mass spectra were recorded on a Model 6110 Quadrupole MSD, Agilent Technologies (Agilent, Santa Clara, CA, USA), and ES-API spectra on a Model 1260 Infinity II Quadrupole MSD, Agilent Technologies. The elemental analysis was run by the London Metropolitan University Elemental Analysis Service. 3,5-Dichloro-4H-1,2,6-thiadiazin-4-one (2) [42], 2-(3,5-dichloro-4H-1,2,6-thiadiazin-4-ylidene)malononitrile (3) [43], and 3-(benzo[d]thiazol-2-ylthio)-5-chloro-4H-1,2,6-thiadiazin-4-one (11h) [26] were prepared according to the literature procedures. 3.2. Chemistry General Procedure 3.2.1. Synthesis of 3-Aminothiadiazines (9a,b, 10a,b, 11a–i, 12a–c) 3-Chloro-5-(4-phenylpiperazin-1-yl)-4H-1,2,6-thiadiazin-4-one (9a) To a stirred mixture of 3,5-dichloro-4H-1,2,6-thiadiazin-4-one (2) (92.0 mg, 0.50 mmol) in EtOH (1 mL) at ca. 20 °C, N-phenylpiperazine was added (76 μL, 0.50 mmol), followed by 2,6-lutidine (58 μL, 0.50 mmol), and the mixture was stirred at this temperature until complete consumption of the starting material (TLC, 1 h). The precipitate formed was then filtered, washed with EtOH (1 mL), then t-BuOMe (1 mL), and dried to give the title compound 9a (82.6 mg, 53%). The filtrate was then adsorbed onto silica and chromatographed (n-hexane/DCM 50:50) to give a further quantity of the title compound 9a (68 mg, total yield 97%) as yellow needles, mp 166–167 °C (from c-hexane); Rf 0.48 (n-hexane/DCM 50:50); (found: C, 50.47; H, 4.07; N, 18.07. C13H13ClN4OS requires C, 50.57; H, 4.24; N, 18.14%); λmax (DCM)/nm 255 (log ε 4.21), 312 (4.21), 320 inf (4.18), 404 (3.74); vmax/cm−1 2901w and 2833w (C-H), 1624s (C=O), 1595m, 1497s, 1344s, 1389m, 1366m, 1277m, 1233s, 1157m, 1094w, 1055w, 1040m, 989m, 955m, 922m, 872s, 854s, 752s; δH (300 MHz; CDCl3) 7.33–7.27 (2H, m, Ar CH), 6.93–6.89 (3H, m, Ar CH), 4.08 (4H, t, J 4.8, Ar CH2), 3.29 (4H, t, J 5.3, Ar CH2); δC (75 MHz; CDCl3) 158.7 (Cq), 152.8 (Cq), 150.7 (Cq), 145.4 (Cq), 129.3 (CH), 120.6 (CH), 116.4 (CH), 49.3 (CH2), 46.6 (CH2); m/z (APCI+) 311 (MH++2, 35%), 309 (MH+, 100), 190 (8), 163 (8), 108 (10), 104 (11). 3-(4-Benzhydrylpiperazin-1-yl)-5-chloro-4H-1,2,6-thiadiazin-4-one (9b) To a stirred mixture of 3,5-dichloro-4H-1,2,6-thiadiazin-4-one (2) (92.0 mg, 0.50 mmol) in EtOH (1 mL) at ca. 20 °C, 1-benzhydrylpiperazine was added (126 mg, 0.50 mmol), followed by 2,6-lutidine (58 μL, 0.50 mmol), and the mixture was stirred at this temperature until complete consumption of the starting material (TLC, 1 h). The mixture was then adsorbed onto silica and chromatographed (n-hexane/DCM 70:30) to give the title compound 9b (197 mg, 99%) as yellow needles, mp 56–57 °C (from EtOH/H2O); Rf 0.24 (n-hexane/DCM 70:30); (found: C, 60.45; H, 4.66; N, 14.01. C20H19ClN4OS requires C, 60.22; H, 4.80; N, 14.05%); λmax (DCM)/nm 268 (log ε 3.98), 312 (4.21), 322 (4.18), 408 (3.76); vmax/cm−1 3021w (C-H arom), 2810w (C-H alip), 1626s (C=O), 1503s, 1441m, 1300m, 1283m, 1260s, 1190s, 1123m, 1142m, 1103m, 1076m, 1051m, 1030m, 995s, 953s, 922m, 876s, 854s, 838m, 764s, 746s, 725m, 704s; δH (500 MHz; CDCl3) 7.42 (4H, d, J 7.2, Ar CH), 7.29 (4H, dd, J 7.4, 7.4, Ar CH), 7.20 (2H, dd, J 7.4, 7.4, Ar CH), 4.25 (1H, s, NCH), 3.90 (4H, s, CH2), 2.49 (4H, t, J 5.0, CH2); δC (125 MHz; CDCl3) 158.7 (Cq), 152.8 (Cq), 145.0 (Cq), 142.0 (Cq), 128.6 (CH), 127.9 (CH), 127.2 (CH), 76.0 (CH), 51.8 (CH2), 46.9 (CH2); m/z (ESI+) 423 (M+Na++2, 5), 421 (M+Na+, 14), 401 (MH++2, 3%), 399 (MH+, 7), 381 (27), 325 (36), 167 (Ph2CH+, 100). 2-[3-Chloro-5-(4-phenylpiperazin-1-yl)-4H-1,2,6-thiadiazin-4-ylidene]malononitrile (10a) To a stirred mixture of 2-(3,5-dichloro-4H-1,2,6-thiadiazin-4-ylidene)malononitrile (3) (116 mg, 0.50 mmol) in DCM (2 mL) at ca. 0 °C, N-phenylpiperazine was added (76 μL, 0.50 mmol), followed by 2,6-lutidine (58 μL, 0.50 mmol), and the mixture was left to warm to ca. 20 °C and stirred until complete consumption of the starting material (TLC, 1 h). The mixture was then adsorbed onto silica and chromatographed (n-hexane/DCM 50:50) to give the title compound 10a (157 mg, 88%) as red plates, mp 114–115 °C (from EtOH/H2O); Rf 0.40 (n-hexane/DCM 50:50); (found: C, 53.92; H, 3.45; N, 23.39. C16H13ClN6O requires C, 53.86; H, 3.67; N, 23.55%); λmax (DCM)/nm 251 (log ε 4.30), 330 (3.98), 491 (3.97); vmax/cm−1 2955w, 2918w, 2889w and 2849w (C-H), 2210 (C≡N), 1597m, 1493s, 1479s, 1435s, 1391m, 1385m, 1364m, 1337m, 1294m, 1267m, 1227s, 1188w, 1150m, 1069m, 1034w, 999m, 935s, 916m, 851m, 826s, 775m, 760s, 733s; δH (500 MHz; CDCl3) 7.30 (2H, dd, J 8.6, 7.3, Ar CH), 6.96–6.92 (3H, m, Ar CH), 3.75 (2H, br. s, CH2), 3.84 (6H, br. s, CH2); δC (125 MHz; CDCl3) 150.5 (Cq), 147.6 (Cq), 134.4 (Cq), 134.0 (Cq), 129.3 (CH), 121.0 (CH), 116.9 (CH), 113.3 (Cq), 112.3 (Cq), 75.6 (Cq), 48.3 (CH2), 48.0 (CH2); m/z (APCI+) 359 (MH++2, 33%), 357 (MH+, 100), 238 (10), 146 (16). 2-[3-(4-Benzhydrylpiperazin-1-yl)-5-chloro-4H-1,2,6-thiadiazin-4-ylidene]malononitrile (10b) To a stirred mixture of 2-(3,5-dichloro-4H-1,2,6-thiadiazin-4-ylidene)malononitrile (3) (116 mg, 0.50 mmol) in DCM (2 mL) at ca. 0 °C, 1-benzhydrylpiperazine was added (126 mg, 0.50 mmol), followed by 2,6-lutidine (58 μL, 0.50 mmol), and the mixture was left to warm to ca. 20 °C and stirred until complete consumption of the starting material (TLC, 1 h). The mixture was then adsorbed onto silica and chromatographed (n-hexane/DCM 50:50) to give the title compound 10b (223 mg, 100%) as orange needles, mp 204–205 °C (from EtOH); Rf 0.39 (n-hexane/DCM 50:50); (found: C, 61.97; H, 4.13; N, 18.56. C23H19ClN6S requires C, 61.81; H, 4.28; N, 18.80%); λmax (DCM)/nm 249 inf (log ε 3.97), 330 (4.06), 381 inf (3.66), 499 (4.04); vmax/cm−1 3071w, 3040w and 3024w (C-H arom), 2997w, 1984w, 2957w, 2912w and 2886 (C-H alip), 2214m (C≡N), 1516s, 1498s, 1446m, 1437s, 1400m, 1342w, 1308m, 1300m, 1290m, 1273m, 1256w, 1234m, 1207w, 1188m, 1150m, 1140m, 1113m, 1103m, 1074m, 1067m, 1055w, 1030w, 991m, 968w, 932m, 864m, 854m, 827m, 814s, 777m, 756m, 745m, 729s, 704s; δH (500 MHz; CDCl3) 7.41 (4H, d, J 7.5, Ar CH), 7.28 (4H, dd, J 7.4, 7.4, Ar CH), 7.20 (2H, dd, J 7.4, 7.4, Ar CH), 4.28 (1H, s, NCH), 3.60 (2H, br. s, CH2), 3.33 (2H, br. s, CH2), 2.59 (4H, br. s, CH2); δC (125 MHz; CDCl3) 147.4 (Cq), 142.0 (Cq), 134.1 (Cq), 134.0 (Cq), 128.7 (CH), 127.8 (CH), 127.3 (CH), 113.3 (Cq), 112.4 (Cq), 75.8 (CH), 75.2 (Cq), 50.5 (CH2), 48.3 (CH2); m/z (ESI+) 449 (MH++2, 3%), 447 (MH+, 5), 381 (5), 325 (15), 167 (Ph2CH+, 100). 3.2.2. Synthesis of 3-thiothiadiazines 3-Chloro-5-[(4-methylpyrimidin-2-yl)thio]-4H-1,2,6-thiadiazin-4-one (11a) To a stirred mixture of 3,5-dichloro-4H-1,2,6-thiadiazin-4-one (2) (92.0 mg, 0.50 mmol) in THF (2 mL) at ca. 20 °C, 4-methylpyrimidine-2-thiol was added (63.0 mg, 0.50 mmol), followed by Et3N (69 μL, 0.50 mmol), and the mixture was stirred at this temperature until complete consumption of the starting material (TLC, 24 h). The mixture was then adsorbed onto silica and chromatographed (DCM) to give the title compound 11a (111 mg, 81%) as yellow needles, mp 119–120 °C (from DCE/c-hexane); Rf 0.43 (DCM); (found: C, 35.36; H, 1.72; N, 20.39. C8H5ClN4OS2 requires C, 35.23; H, 1.85; N, 20.54%); λmax (DCM)/nm 241 inf (log ε 4.10), 285 inf (4.13), 315 (4.32), 357 (4.22); vmax/cm−1 1643s (C=O), 1572s, 1534w, 1491m, 1431w, 1416m, 1371w, 1339m, 1281m, 1273m, 1240w, 1200m, 1186m, 1099w, 1059m, 1045w, 899w, 878w, 856m, 849m, 762m, 736s, 721s; δH (300 MHz; DMSO-d6) 8.68 (1H, d, J 5.4, Ar CH), 7.41 (1H, d, J 5.0, Ar CH), 2.47 (3H, s, CH3); δC (75 MHz; DMSO-d6) 169.1 (Cq), 163.7 (Cq), 160.3 (Cq), 158.8 (Cq), 158.4 (CH), 145.4 (Cq), 120.2 (CH), 23.4 (CH3); m/z (APCI+) 275 (MH++2, 39%), 273 (MH+, 100), 237 (10). 3-Chloro-5-[(1-methyl-1H-tetrazol-5-yl)thio]-4H-1,2,6-thiadiazin-4-one (11b) To a stirred mixture of 3,5-dichloro-4H-1,2,6-thiadiazin-4-one (2) (92.0 mg, 0.50 mmol) in THF (2 mL) at ca. 20 °C, 1-methyl-1H-tetrazole-5-thiol was added (58.0 mg, 0.50 mmol), followed by Et3N (69 μL, 0.50 mmol), and the mixture was stirred at this temperature until complete consumption of the starting material (TLC, 5 h). The mixture was then adsorbed onto silica and chromatographed (DCM) to give the title compound 11b (36 mg, 28%) as yellow needles, mp 215–216 °C (from EtOH); Rf 0.42 (DCM); (found: C, 22.73; H, 1.38; N, 31.75. C5H3ClN6OS2 requires C, 22.86; H, 1.15; N, 31.99%); λmax (DCM)/nm 305 (log ε 4.17), 347 (4.23); vmax/cm−1 1634s (C=O), 1493m, 1470w, 1396w, 1285m, 1263w, 1244w, 1204w, 1180m, 1065s, 984w, 932w, 905w, 862m, 748s, 721m; δH (500 MHz; DMSO-d6) 4.04 (3H, s, CH3); δC (125 MHz; DMSO-d6) 159.2 (Cq), 158.1 (Cq), 146.3 (Cq), 144.4 (Cq), 34.5 (CH3); m/z (APCI+) 264 (M++2, 3%), 262 (M+, 5), 120 (100). 3-(Benzo[d]oxazol-2-ylthio)-5-chloro-4H-1,2,6-thiadiazin-4-one (11c) To a stirred mixture of 3,5-dichloro-4H-1,2,6-thiadiazin-4-one (2) (92.0 mg, 0.50 mmol) in THF (2 mL) at ca. 20 °C, benzo[d]oxazole-2-thiol was added (76.0 mg, 0.50 mmol), followed by Et3N (69 μL, 0.50 mmol), and the mixture was stirred at this temperature until complete consumption of the starting material (TLC, 20 h). The solvent was then evaporated under vacuum, EtOH (5 mL) added and the precipitate filtered, washed with EtOH (1 mL) and dried to give the title compound 11c (110 mg, 74%) as brown needles, mp 277–279 °C (from PhMe/DMA); Rf 0.71 (DCM); (found: C, 40.26; H, 1.47; N, 13.96. C10H4ClN3O2S2 requires C, 40.34; H, 1.35; N, 14.11%); λmax (DCM)/nm 293 inf (log ε 4.20), 313 (4.32), 346 inf (4.17); vmax/cm−1 1645s (C=O), 1504m, 1497m, 1472w, 1449m, 1337w, 1300m, 1287w, 1248m, 1213m, 1123m, 1094s, 1067w, 1003w, 934m, 891w, 804m, 760s, 750s, 729s; δH (500 MHz; DMSO-d6) 7.89 (1H, d, J 7.8, Ar CH), 7.84 (1H, d, J 8.2, Ar CH), 7.54 (1H, ddd, J 7.7, 7.7, 1.1, Ar CH), 7.48 (1H, ddd, J 7.7, 7.7, 0.8, Ar CH); δC (125 MHz; DMSO-d6) 159.4 (Cq), 158.9 (Cq), 154.2 (Cq), 152.3 (Cq), 144.6 (Cq), 141.2 (Cq), 126.9 (CH), 125.2 (CH), 120.3 (CH), 111.2 (CH); m/z (MALDI-TOF) 300 (MH++2, 4%), 298 (MH+, 9), 193 (13), 177 (35), 137 (53), 102 (100). N-{4-[(5-Chloro-4-oxo-4H-1,2,6-thiadiazin-3-yl)thio]phenyl}acetamide (11d) To a stirred mixture of 3,5-dichloro-4H-1,2,6-thiadiazin-4-one (2) (92.0 mg, 0.50 mmol) in THF (2 mL) at ca. 20 °C, N-(4-mercaptophenyl)acetamide was added (84.0 mg, 0.50 mmol), followed by Et3N (69 μL, 0.50 mmol), and the mixture was stirred at this temperature until complete consumption of the starting material (TLC, 1 h). The mixture was then adsorbed onto silica and chromatographed (DCM/t-BuOMe 50:50) to give the title compound 11d (127 mg, 81%) as yellow needles, mp 191–192 °C (from EtOH); Rf 0.62 (DCM/t-BuOMe 50:50); (found: C, 42.14; H, 2.49; N, 13.32. C11H8ClN3O2S2 requires C, 42.11; H, 2.57; N, 13.39%); λmax (DCM)/nm 278 (log ε 4.22), 294 (4.25), 358 (4.08), 416 (3.76); vmax/cm−1 3319w (N-H), 1670m and 1649s (C=O), 1589m, 1518m, 1485m, 1458w, 1398m, 1368m, 1354m, 1294m, 1271m, 1261m, 1244m, 1180m, 1061m, 829m, 746s, 721m, 716m; δH (300 MHz; DMSO-d6) 10.19 (1H, s, NH), 7.70 (2H, d, J 8.7, Ar CH), 7.43 (2H, d, J 8.7, Ar CH), 2.07 (3H, s, CH3); δC (75 MHz; DMSO-d6) 168.7 (Cq), 163.5 (Cq), 159.2 (Cq), 143.5 (Cq), 141.0 (Cq), 135.9 (CH), 119.8 (CH), 119.2 (Cq), 24.0 (CH3); m/z (APCI+) 316 (MH++2, 42%), 314 (MH+, 100). 3-Chloro-5-[(1-phenyl-1H-tetrazol-5-yl)thio]-4H-1,2,6-thiadiazin-4-one (11e) To a stirred mixture of 3,5-dichloro-4H-1,2,6-thiadiazin-4-one (2) (92.0 mg, 0.50 mmol) in THF (2 mL) at ca. 20 °C, 1-phenyl-1H-tetrazole-5-thiol was added (63.0 mg, 0.50 mmol), followed by Et3N (69 μL, 0.50 mmol), and the mixture was stirred at this temperature until complete consumption of the starting material (TLC, 5 h). The mixture was then adsorbed onto silica and chromatographed (n-hexane/DCM 20:80) to give the title compound 11e (64 mg, 39%) as colorless plates, mp 182–183 °C (from EtOH); Rf 0.16 (n-hexane/DCM 20:80); (found: C, 37.06; H, 1.40; N, 25.54. C10H5ClN6OS2 requires C, 36.98; H, 1.55; N, 25.88%); λmax (MeCN)/nm 235 inf (log ε 4.19), 305 (4.26), 347 (4.30); vmax/cm−1 3100w and 3063w (C-H arom), 1655s (C=O), 1497m, 1485m, 1418w, 1406m, 1279m, 1244w, 1219m, 1123w, 1067m, 1015w, 760s, 745s, 727m; δH (300 MHz; CDCl3) 7.60–7.51 (5H, m, Ar CH); δC (125 MHz; CDCl3) 159.0 (Cq), 158.1 (Cq), 146.2 (Cq), 145.3 (Cq), 133.2 (Cq), 131.1 (CH), 129.9 (CH), 124.6 (CH); m/z (MALDI-TOF) 327 (MH++2, 31%), 325 (MH+, 82), 279 (54), 220 (46), 128 (100), 100 (49). 3-Chloro-5-[(4-methyl-4H-1,2,4-triazol-3-yl)thio]-4H-1,2,6-thiadiazin-4-one (11f) To a stirred mixture of 3,5-dichloro-4H-1,2,6-thiadiazin-4-one (2) (92.0 mg, 0.50 mmol) in THF (2 mL) at ca. 20 °C, 4-methyl-4H-1,2,4-triazole-3-thiol was added (58.0 mg, 0.50 mmol), followed by Et3N (69 μL, 0.50 mmol), and the mixture was stirred at this temperature until complete consumption of the starting material (TLC, 3 h). The precipitate was then filtered, washed with EtOH (5 mL) and dried to give the title compound 11f (106 mg, 81%) as yellow needles, mp 152–153 °C (from THF/EtOH); Rf 0.18 (DCM/t-BuOMe 50:50); (found: C, 27.69; H, 1.46; N, 26.74. C6H4ClN5OS2 requires C, 27.54; H, 1.54; N, 26.76%); λmax (DCM)/nm 263 (log ε 4.60), 291 (4.60), 346 (4.11); vmax/cm−1 2959w, 2920w and 2853w (C-H), 1624s (C=O), 1506m, 1470w, 1418w, 1290m, 1254w, 1192m, 1163w, 1065m, 1016w, 957w, 856m, 748s, 733m; δH (500 MHz; DMSO-d6) 8.85 (1H, s, Ar CH), 3.60 (3H, s, CH3); δC (125 MHz; DMSO-d6) 159.7 (Cq), 159.3 (Cq), 148.2 (CH), 144.3 (Cq), 141.8 (Cq), 31.3 (CH3); m/z (MALDI-TOF) 264 (MH++2, 25%), 262 (MH+, 65), 184 (23), 100 (100). 3-Chloro-5-(thiazol-2-ylthio)-4H-1,2,6-thiadiazin-4-one (11g) To a stirred mixture of 3,5-dichloro-4H-1,2,6-thiadiazin-4-one (2) (92.0 mg, 0.50 mmol) in THF (2 mL) at ca. 20 °C, thiazole-2-thiol was added (59.0 mg, 0.50 mmol), followed by Et3N (69 μL, 0.50 mmol), and the mixture was stirred at this temperature until complete consumption of the starting material (TLC, 1 h). The mixture was then adsorbed onto silica and chromatographed (n-hexane/DCM 20:80) to give the title compound 11g (96 mg, 73%) as yellow needles, mp 136–137 °C (from EtOH); Rf 0.29 (n-hexane/DCM 20:80); (found: C, 27.17; H, 0.54; N, 15.79. C6H2ClN3OS3 requires C, 27.33; H, 0.76; N, 15.93%); λmax (DCM)/nm 247 (log ε 3.94), 308 (4.16), 352 (4.08); vmax/cm−1 3053w (C-H arom), 1643s (C=O), 1605w, 1567w, 1491m, 1468m, 1350m, 1312m, 1279m, 1260w, 1242w, 1159w, 1063s, 1034s, 741s, 719s; δH (300 MHz; CDCl3) 8.04 (1H, d, J 3.4, Ar CH), 7.68 (1H, d, J 3.3, Ar CH); δC (125 MHz; DMSO-d6) 160.1 (Cq), 159.0 (Cq), 152.4 (Cq), 144.2 (Cq), 144.1 (CH), 126.8 (CH); m/z (MALDI-TOF) 266 (MH++2, 68%), 264 (MH+, 100), 247 (90), 232 (42), 142 (29). 3-Chloro-5-[(6-ethoxybenzo[d]thiazol-2-yl)thio]-4H-1,2,6-thiadiazin-4-one (11i) To a stirred mixture of 3,5-dichloro-4H-1,2,6-thiadiazin-4-one (2) (92.0 mg, 0.50 mmol) in THF (2 mL) at ca. 20 °C, 6-ethoxybenzo[d]thiazole-2-thiol was added (106 mg, 0.50 mmol), followed by Et3N (69 μL, 0.50 mmol), and the mixture was stirred at this temperature until complete consumption of the starting material (TLC, 2 h). The mixture was then adsorbed onto silica and chromatographed (n-hexane/DCM 20:80) to give the title compound 11i (77 mg, 43%) as yellow needles, mp 180–181 °C (from DCE/EtOH); Rf 0.32 (n-hexane/DCM 20:80); (found: C, 40.19; H, 2.55; N, 11.48. C12H8ClN3O2S3 requires C, 40.28; H, 2.25; N, 11.74%); λmax (MeCN)/nm 213 (log ε 4.44), 222 inf (4.41), 256 (3.99), 314 (4.32), 346 inf (4.14); vmax/cm−1 3088w and 3061w (C-H arom), 2994w, 2943w and 2891w (C-H alip), 1634s (C=O), 1595m, 1558w, 1541w, 1481m, 1460m, 1431m, 1396m, 1321w, 1273m, 1260s, 1229s, 1130w, 1107w, 1066m, 1036m, 1016m, 939m, 851m, 827m, 746s, 725m; δH (300 MHz; DMSO-d6) 7.96 (1H, d, J 8.9, Ar CH), 7.74 (1H, d, J 2.5, Ar CH), 7.17 (1H, ddd, J 9.0, 2.5, Ar CH), 4.11 (2H, q, J 7.0, OCH2), 1.37 (3H, t, J 7.0, CH3); δC (75 MHz; DMSO-d6) 159.7 (Cq), 158.9 (Cq), 157.2 (Cq), 152.3 (Cq), 146.5 (Cq), 144.3 (Cq), 138.8 (CH), 123.6 (CH), 116.7 (CH), 105.0 (CH), 63.8 (CH2), 14.5 (CH3); m/z (MALDI-TOF) 360 (MH++2, 24%), 358 (MH+, 56), 280 (100), 233 (29), 210 (40), 182 (30). 2-{3-Chloro-5-[(4-methylpyrimidin-2-yl)thio]-4H-1,2,6-thiadiazin-4-ylidene}malononitrile (12a) To a stirred mixture of 2-(3,5-dichloro-4H-1,2,6-thiadiazin-4-ylidene)malononitrile (3) (116 mg, 0.50 mmol) in DCM (5 mL) at ca. 0 °C, 4-methylpyrimidine-2-thiol was added (63.0 mg, 0.50 mmol), followed by Hünig’s base (87 μL, 0.50 mmol), and the mixture was left to warm to ca. 20 °C and stirred until complete consumption of the starting material (TLC, 30 min). The mixture was then adsorbed onto silica and chromatographed (n-hexane/DCM 20:80) to give the title compound 12a (114 mg, 71%) as yellow needles, mp 126–127 °C (from c-hexane); Rf 0.86 (n-hexane/DCM 20:80); (found: C, 41.36; H, 1.43; N, 26.17. C11H5ClN6S2 requires C, 41.19; H, 1.57; N, 26.20%); λmax (DCM)/nm 238 (log ε 4.28), 271 inf (4.09), 353 (4.06), 424 (4.28); vmax/cm−1 2226m (C≡N), 1574s, 1537s, 1504w, 1487m, 1454m, 1435m, 1418m, 1373w, 1344m, 1337s, 1333s, 1285s, 1204m, 1182m, 1157m, 1105m, 1096m, 1078w, 943w, 883m, 851m, 810m, 795m, 785s, 764m, 754s, 716s; δH (500 MHz; CDCl3) 8.43 (1H, d, J 5.0, Ar CH), 7.04 (1H, d, J 5.0, Ar CH), 2.50 (3H, s, CH3); δC (125 MHz; CDCl3) 163.3 (Cq), 166.6 (Cq), 157.6 (CH), 144.7 (Cq), 141.5 (Cq), 137.0 (Cq), 118.7 (CH), 111.9 (Cq), 111.8 (Cq), 79.2 (Cq), 24.2 (CH3); m/z (APCI+) 323 (MH++2, 21%), 321 (MH+, 60), 313 (100), 285 (M+-Cl,), 267 (44), 239 (62), 197 (C6ClN4S++2, 34), 195 (C6ClN4S+, 100), 159 (51). 2-{3-Chloro-5-[(1-methyl-1H-tetrazol-5-yl)thio]-4H-1,2,6-thiadiazin-4-ylidene}malononitrile (12b) To a stirred mixture of 2-(3,5-dichloro-4H-1,2,6-thiadiazin-4-ylidene)malononitrile (3) (116 mg, 0.50 mmol) in DCM (5 mL) at ca. 0 °C, 1-methyl-1H-tetrazole-5-thiol was added (58.0 mg, 0.50 mmol), followed by Hünig’s base (87 μL, 0.50 mmol), and the mixture was left to warm to ca. 20 °C and stirred until complete consumption of the starting material (TLC, 3.5 h). The precipitate formed was then filtered, washed with n-hexane (5 mL), and dried to give the title compound 12b (64 mg, 41%). The filtrate was then adsorbed onto silica and chromatographed (DCM/t-BuOMe 80:20) to give a further quantity of the title compound 12b (23 mg, total yield 56%) as orange needles, mp >300 °C (from DCE/EtOH); Rf 0.48 (DCM/t-BuOMe 80:20); (found: C, 31.06; H, 0.84; N, 36.00. C8H3ClN8S2 requires C, 30.92; H, 0.97; N, 36.06%); λmax (DCM)/nm 240 (log ε 3.99), 314 (3.96), 324 inf (3.94), 359 (3.84), 438 (4.05); vmax/cm−1 2911w (C-H), 2201w (C≡N), 1624s, 1493m, 1470m, 1449m, 1402m, 1377w, 1310m, 1271w, 1207m, 1179m, 1148w, 1069s, 1026w, 986w, 930w, 853w, 831w, 739s, 725s; δH (500 MHz; CD3CN) 4.06 (3H, s, CH3); δC (125 MHz; CD3CN) 146.7 (Cq), 145.1 (Cq), 137.7 (Cq), 114.3 (Cq), 35.6 (CH3), three Cq resonances missing; m/z (APCI+) 313 (MH++2, 19%), 311 (MH+, 20), 273 (41), 265 (41), 263 (97), 199 (33), 185 (100). 2-[3-(Benzo[d]oxazol-2-ylthio)-5-chloro-4H-1,2,6-thiadiazin-4-ylidene]malononitrile (12c) To a stirred mixture of 2-(3,5-dichloro-4H-1,2,6-thiadiazin-4-ylidene)malononitrile (3) (116 mg, 0.50 mmol) in DCM (5 mL) at ca. 0 °C, benzo[d]oxazole-2-thiol was added (76.0 mg, 0.50 mmol), followed by Hünig’s base (87 μL, 0.50 mmol), and the mixture was left to warm to ca. 20 °C and stirred until complete consumption of the starting material (TLC, 3 h). The mixture was then adsorbed onto silica and chromatographed (DCM) to give the title compound 12c (85 mg, 49%) as orange plates, mp 192–193 °C (from c-hexane); Rf 0.65 (DCM); (found: C, 45.38; H, 1.04; N, 20.16. C13H13ClN4OS requires C, 45.16; H, 1.17; N, 20.25%); λmax (DCM)/nm 251 (log ε 4.33), 276 (4.22), 284 (4.22), 425 (4.35); vmax/cm−1 3150w (C-H arom), 2208m (C≡N), 1493m, 1470m, 1445m, 1339w, 1288m, 1265w, 1242w, 1213w, 1146m, 1125m, 1098m, 1076m, 1003w, 961w, 937w, 845w, 818m, 806m, 744s; δH (500 MHz; CDCl3) 7.78 (1H, dd, J 7.3, 1.6, Ar CH), 7.59 (1H, dd, J 7.3, 1.1, Ar CH), 7.47–7.41 (2H, m, Ar CH); δC (125 MHz; CDCl3) 153.7 (Cq), 152.7 (Cq), 146.1 (Cq), 141.4 (Cq), 137.3 (Cq), 136.3 (Cq), 126.8 (CH), 125.4 (CH), 120.6 (CH), 112.3 (Cq), 111.7 (Cq), 111.0 (CH), 79.6 (Cq); m/z (MALDI-TOF) 348 (MH++2, 40%), 346 (MH+, 100), 287 (21), 151 (26). 3.3. Biological In Vitro Assays For the in vitro studies, the synthesized compounds were prepared as a 10 mM stock solution in DMSO. To determine the IC50 values, serial dilutions were performed. Each assay was performed six times, and the standard deviations were less than 10% of the average. 3.3.1. Determination of the Reducing Activity of the Stable Radical DPPH In vitro assays were carried out to evaluate the reducing activity of the novel derivatives against the DPPH stable radical. Free radical scavenging activity was determined by measuring absorbance at 517 nm after 20 and 60 min at room temperature. NDGA served as the reference compound. (Table 4) [44]. 3.3.2. Inhibition of AAPH-Induced Linoleic Acid Peroxidation AAPH was used as an alkyl peroxyl radical inducer. In this experiment, the compounds’ ability to prevent linoleic acid oxidation by alkyl peroxyl radicals through absorbance changes at 234nm was evaluated, corresponding to the production of 13-hydroperoxy-linoleic acid. Trolox was used as the reference compound. The results are presented in Table 4 [44]. 3.3.3. Inhibition of Soybean Lipoxygenase Sodium linoleate (0.1 mM), 0.2 mL of soybean lipoxygenase solution (1/9 × 10−4 w/v in saline), and 10 μL of the test compound stock solution (10 mM in DMSO) were incubated at room temperature. The formation of 13-hydroperoxy-linoleic acid was monitored by measuring absorbance at 234 nm. NDGA was used as the reference compound. A couple of concentrations of the test compounds were used to calculate the IC50 values. The results are presented in Table 4 [44]. 3.4. Computational Methods 3.4.1. Molecular Docking Studies on Soybean Lipoxygenase The protein structure (PDB ID: 3PZW) was visualized and preprocessed using UCSF Chimera (version 1.18) [45]. Chimera was used to remove water molecules and non-essential crystallographic compounds. Missing residues (Met1–Phe2–Ser3–Ala4–Gly5; Glu21–Val22–Asn23–Pro24–Asp25–Gly26–Ser27–Ala28–Val28–Asp29; Ile117–Ser118–Asn119–Gln120) were added using Modeller (v. 10.3) [46]. Hydrogen atoms and partial charges were incorporated using AmberTools 23 [47,48]. A +2.0 charge was assigned to the iron center using the 12-6 Lennard-Jones (LJ) non-bonded model. [49]. Histidine residues (His499, His504, His690), which coordinate the iron, were modeled as neutral with δ-nitrogen protonation. For solvation, the simulated box kept a minimum of 12 Å between the solute and the box boundary using the TIP3P water model. Ligand 3D structures were generated and minimized using Open Babel (v. 3.1.1) [50] with the MMFF94 force field [51]. Ligand topologies and parameters were generated with ACPYPE [52], employing AnteChamber (AmberTools v. 22.10) [53]. Energy minimization of the protein was performed using GROMACS (v. 4.6.5). [54]. Ligand docking was carried out with AutoDock Vina (v. 1.2.3) [55], using a grid box centered at x = 1.35 Å, y = 14.3 Å, z = −34.60 Å, and with dimensions x = 100 Å, y = 70 Å, z = 70 Å. The exhaustiveness was set to 10, with up to 20 docking modes generated. Docking outcomes were examined using UCSF Chimera. 3.4.2. In Silico Determination of Drug-likeness and Lipophilicity The compounds’ drugability was performed using the online software Molinspiration (https://www.molinspiration.com/, accessed on 9 September). Lipophilicity was theoretically calculated as clog p values by the Bio-Loom program of BioByte Corp (http://biobyte.com/bb/prod/bioloom.html, accessed on 9 June 2025) [56]. 4. Conclusions Fifteen novel 1,2,6-thiadiazine derivatives were synthesized via mono-displacement of dichlorothiadiazinone 2 and dicyanoylidene 3 with amine and thiol nucleophiles. All the compounds were evaluated for antioxidant activity (DPPH radical scavenging and AAPH-induced lipid peroxidation) and anti-inflammatory potential (soybean lipoxygenase inhibition). Structural characterization was confirmed by melting point and spectroscopic analysis (IR, 1H/13C NMR, MS). Compounds 9a,b, 10a,b, and 11a–i showed low, time-independent DPPH activity, whereas compounds 12a–c exhibited markedly enhanced scavenging, with 12c and 12a reaching 92% and 90% interaction at 60 min, respectively. The superior activity of 12a–c compared to 11a–c indicates that a 4-dicyanoylidine group in the thiadiazine, instead of a ketone, is more favorable for DPPH interaction. Similarly, AAPH inhibition was low in the 9a,b and 10a,b series and moderate to low in 11a–i, while 12c demonstrated the strongest effect (70%, at 100 µM), further supporting the beneficial role of the 4-dicyanoylidine group. sLOX inhibition was generally moderate to low, except for compound 9a (IC50 = 7.5 µM), which bears ketone and phenyl substitutions. Overall, compound 12c emerged as the most potent antioxidant across both DPPH and AAPH assays, while 9a showed the most significant lipoxygenase inhibitory activity. These results highlight the influence of specific substitutions on the biological activity of 1,2,6-thiadiazine derivatives and provide guidance for further optimization. Acknowledgments The authors thank the following organizations and companies in Cyprus for generous donations of chemicals and glassware: The State General Laboratory, the Agricultural Research Institute, the Ministry of Agriculture, MedoChemie Ltd., Medisell Ltd., and Biotronics Ltd. Furthermore, we thank the A.G. Leventis Foundation for helping to establish the NMR facility at the University of Cyprus. Abbreviations The following abbreviations are used in this manuscript: AAPH2,2′-Azobis(2-amidinopropane) dihydrochlorideADMETAbsorption, Distribution, Metabolism, Excretion, ToxicityDCMDichloromethaneDPPH2,2-diphenyl-1-picrylhydrazylEtOHEthanolGPXGlutathione peroxidaseMWMolecular weightNDGANordihydroguaiaretic acidOSOxidative stressPIDA(Diacetoxyiodo)benzeneROSReactive oxygen speciesSODSuperoxide dismutasesLOXSoybean lipoxygenaseTHFTetrahydrofuranTLCThin-layer chromatographyTPSATopological polar surface areaUv/visUltraviolet/visible light Supplementary Materials The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/ijms262411817/s1. Author Contributions A.S.K., P.A.K. and E.P. contributed to the conceptualization and methodology. A.S.K. performed the synthesis experiments and analyzed the characterization data. E.C. performed the biological assays of the novel derivatives. A.S.K., E.P. and E.C. contributed to the writing and preparation of the manuscript. A.S.K., P.A.K. and E.P. contributed to the supervision, writing, reviewing, and editing of this manuscript. All authors have read and agreed to the published version of the manuscript. Institutional Review Board Statement Not applicable. Informed Consent Statement Not applicable. Data Availability Statement The original contributions presented in this study are included in the article/Supplementary Materials. Further inquiries can be directed to the corresponding authors. Conflicts of Interest The authors declare no conflicts of interest. Funding Statement This research was funded by the Cyprus Research Promotion Foundation, grant numbers ΣΤΡAΤHΙΙ/0308/06, NEKYP/0308/02 ΥΓΕΙA/0506/19, and ΕΝΙΣΧ/0308/83. Footnotes Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. References Associated Data Supplementary Materials Data Availability Statement The original contributions presented in this study are included in the article/Supplementary Materials. Further inquiries can be directed to the corresponding authors.